Biocon informs about updates

07 Oct 2022 Evaluate
Biocon has informed that the European Directorate for the Quality of Medicines & HealthCare (EDQM) conducted a GMP inspection of an API manufacturing site of Biocon in Bangalore from the 12th to 14th of September 2022 and issued a list of deficiencies on 5th October 2022. There were no critical deficiencies and one deficiency cited under the category 'Major'. The company will be responding to the agency with appropriate corrective and preventive actions within the stipulated time. Biocon remains committed to the Quality, Safety & Efficacy of its products.' The above information will also be available on the website of the Company at www.biocon.com. 

The above information is a part of company’s filings submitted to BSE.

Biocon Share Price

366.40 -6.25 (-1.68%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×